| This meeting was only intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s). Prescribing information was available at the meeting and is available in the links below. |
| Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com. |
Exploring the current headache landscape- what do the new guidelines mean for patient practice?
From Head Start's Annual Meeting, June 2024
Discuss what the new guidelines mean for patient practice with Dr Jane Anderson
Dr Jane Anderson provides an overview of the current landscape of headaches, focusing on the impact of migraines in the UK on individuals, families, and society. She discusses treatment goals for patients, highlights the new NICE guidelines, and addresses challenges currently facing clinical practice, such as regional disparities in care and rising costs.
Dr Anderson emphasises the need to prioritise improvements in the migraine care pathway, advocating for the creation of community service hubs to ensure comprehensive care at all levels, standardisation of treatment approaches across regions, and the integration of gepants into both community and secondary care settings.
Abbreviations
CGRP, calcitonin gene-related peptide; FASPS2, familial advanced sleep phase syndrome-2; HRT, hormone replacement therapy; ICS, integrated care systems; NICE, National Institute for Health and Care Excellence.
Discover more about Head Start's Annual Meeting
Prescribing Information
More from Teva
This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.
Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited
Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.
Privacy Policy | Pharmacovigilance Privacy Policy | Terms and Conditions | Accessibility | Reporting Adverse Events